Core Viewpoint - Amgen reported strong Q3 earnings, exceeding expectations with a revenue of $9.6 billion, a 12% year-over-year increase, and raised its full-year guidance for 2025 [1][12][30] Financial Performance - Total revenue for Q3 reached $9.6 billion, up 12% year-over-year, driven by a 14% increase in sales volume [11][15] - Non-GAAP operating margin was 47%, with free cash flow of $4.2 billion [15][28] - The company raised its 2025 revenue guidance to between $35.8 billion and $36.6 billion, and adjusted non-GAAP EPS guidance to $20.60–$21.40 [3][30] Product Highlights - Repatha sales reached $794 million, a 40% increase year-over-year, significantly exceeding analyst expectations [3][32] - Tezspire sales grew by 40% to $377 million, benefiting from recent approvals for chronic rhinosinusitis [5][37] - Uplizna generated $155 million in sales, a 46% increase, with upcoming FDA approval for generalized myasthenia gravis [6][35] - Prolia sales were $1.1 billion, a 9% increase, surpassing analyst forecasts [7][16] Research and Development - The VESALIUS-CV trial showed that Repatha significantly reduces major adverse cardiovascular events (MACE) in high-risk patients, with results to be presented at the AHA meeting [4][43] - MariTide, a weight management drug, is in six Phase III trials, showing promising results in cardiovascular risk factors [8][41] Market Strategy - Amgen launched AmgenNow, a direct-to-consumer platform for Repatha, priced at $239 per month, enhancing patient accessibility [5][33] - The company plans to invest over $3 billion in U.S. manufacturing in 2025, continuing its commitment to expand production capabilities [12][22] Future Outlook - Amgen is optimistic about the growth potential of its pipeline, particularly in obesity and cardiovascular disease with MariTide and Olpasiran [10][24] - The company expects continued investment in R&D, with a projected 20% increase in non-GAAP R&D expenses for 2025 [14][30]

Group 1 - Amgen's stock rose over 8% following the release of its third-quarter results, indicating strong investor confidence [1] - The company reported a 12% year-over-year increase in total revenue, reaching $9.6 billion, driven by significant sales growth of key drugs [2] - Non-GAAP net income increased by 1% to just under $3.06 billion, or $5.64 per share, surpassing analyst expectations [2][3] Group 2 - Amgen attributed its better-than-expected performance to volume growth and emphasized its focus on expanding access and innovation for long-term growth [4] - The company raised its full-year 2025 revenue guidance to a range of $35.8 billion to $36.6 billion, up from the previous range of $35 billion to $36 billion [5] - Adjusted net income forecast was also increased to $20.60 to $21.40 per share, compared to the prior forecast of $20.20 to $21.30 [5]

Core Insights - Amgen reported third-quarter 2025 adjusted earnings of $5.64 per share, exceeding the Zacks Consensus Estimate of $5.00 per share, with a year-over-year earnings increase of 1% driven by higher revenues despite increased operating costs and taxes [1] - Total revenues reached $9.6 billion, surpassing the Zacks Consensus Estimate of $8.9 billion, marking a 12% year-over-year increase [1] Revenue Breakdown - Total product revenues increased by 12% year-over-year to $9.17 billion, with volume growth of 14% offset by a 4% negative impact from pricing [2] - Other revenues amounted to $420 million, reflecting a 19.3% year-over-year increase [2] Key Drug Performance - Evenity sales reached $541 million, up 36% year-over-year, exceeding both the Zacks Consensus Estimate of $519 million and the model estimate of $463.9 million [3] - Repatha generated revenues of $794 million, a 40% year-over-year increase, beating the Zacks Consensus Estimate of $720 million and the model estimate of $672.2 million [3] - Prolia revenues were $1.14 billion, up 9% year-over-year, significantly surpassing the Zacks Consensus Estimate of $911 million and the model estimate of $812.8 million [4] - Xgeva delivered revenues of $539 million, flat year-over-year, but exceeded the Zacks Consensus Estimate of $428 million and the model estimate of $408.6 million [5] - Blincyto sales were $392 million, a 20% increase year-over-year, but missed the Zacks Consensus Estimate of $413 million [7] - Otezla sales were $585 million, up 4% year-over-year, beating the Zacks Consensus Estimate of $582 million but missing the model estimate of $648.2 million [8] - Enbrel revenues declined by 30% year-over-year to $580 million, missing the Zacks Consensus Estimate of $645 million but beating the model estimate of $530.4 million [9] - Tezspire recorded sales of $377 million, a 40% year-over-year increase, exceeding both the Zacks Consensus Estimate of $364 million and the model estimate of $270.6 million [10] Cost and Margin Analysis - Adjusted operating margin decreased by 2.5 percentage points to 47.1%, with adjusted operating expenses rising by 18% to $5.25 billion [14] - R&D expenses increased by 31% year-over-year to $1.89 billion, reflecting ongoing investment in the late-stage pipeline [14] Future Outlook - Amgen raised its 2025 revenue and earnings guidance, expecting total revenues between $35.8 billion and $36.6 billion, and adjusted earnings per share in the range of $20.60 to $21.40 [15] - The company anticipates continued growth from key drugs like Repatha, Evenity, Tezspire, and its biosimilar portfolio, although erosion from biosimilars of Prolia and Xgeva may offset some growth [21] Pipeline Developments - Amgen is advancing its obesity drug MariTide, which has shown strong efficacy in clinical studies, with six global phase III studies currently underway [16][17] - Enrollment has been completed in two phase III studies for MariTide, with ongoing studies for cardiovascular disease and heart failure [18]

Core Viewpoint - The healthcare sector has underperformed compared to the broader market in recent years, yet Amgen Inc. (AMGN) presents attractive growth opportunities for long-term investors [1] Group 1: Company Analysis - Amgen Inc. is highlighted as a company with strong growth prospects despite the overall sector's lagging performance [1] - The investment strategy includes a mix of classic dividend growth stocks, Business Development Companies, REITs, and Closed End Funds to enhance investment income while achieving total returns comparable to traditional index funds [1] Group 2: Investment Strategy - A hybrid investment approach combining growth and income is suggested as an effective method to achieve returns on par with the S&P [1]

Although the healthcare sector has lagged behind the rest of the market over the last few years, I believe that Amgen Inc. ( AMGN ) still offers attractive growth prospects to long-term investors. TheFinancial analyst by day and a seasoned investor by passion, I've been involved in the world of investing for over 15 years and honed my skills in analyzing lucrative opportunities within the market.I specialize in uncovering high quality dividend stocks and other assets that offer potential for long term-growt ...

Core Insights - Amgen (AMGN.US) shares rose by 6% to $314.58 following strong Q3 earnings results [1] - The company's Q3 sales increased by 12% year-over-year to $9.56 billion, surpassing analyst expectations of $8.97 billion [1] - Adjusted earnings per share (EPS) were reported at $5.64, exceeding the forecast of $5.01 [1] - Amgen raised its full-year guidance, projecting sales between $35.8 billion and $36.6 billion, and EPS between $20.6 and $21.4 [1]

Core Viewpoint - Amgen (AMGN.US) reported a strong performance in Q3, with sales and earnings exceeding analyst expectations, leading to an upward revision of its full-year guidance [1] Financial Performance - Q3 sales increased by 12% year-over-year to $9.56 billion, surpassing analyst expectations of $8.97 billion [1] - Adjusted earnings per share (EPS) were $5.64, exceeding the forecast of $5.01 [1] Guidance Update - The company raised its full-year sales guidance to a range of $35.8 billion to $36.6 billion [1] - Full-year EPS is now expected to be between $20.6 and $21.4 [1]

Core Insights - Amgen (AMGN.US) shares rose over 5.6%, reaching a high of $313.36, marking a new high in over 7 months [1] Financial Performance - In Q3, Amgen's sales increased by 12% year-over-year to $9.56 billion, surpassing analyst expectations of $8.97 billion [1] - Adjusted earnings per share (EPS) were reported at $5.64, exceeding the forecast of $5.01 [1] Guidance Update - The company raised its full-year performance guidance, projecting sales between $35.8 billion and $36.6 billion, and EPS between $20.6 and $21.4 [1]

Corporate Earnings Drive Pre-Market Activity - Amgen Inc. reported a 12% increase in total revenues to $9.6 billion and non-GAAP EPS of $5.64, exceeding forecasts and leading to a 3% rise in stock [3] - Lumentum Holdings Inc. saw a 17% stock increase after reporting Q3 2025 EPS of $0.57 on revenues of $425.2 million, driven by growth in its Cloud and Networking segment [4] - Rivian Automotive, Inc. reported Q3 2025 revenues of $1.56 billion, surpassing estimates, with a narrower loss per share of -$0.65 and a 47% year-over-year increase in automotive sales [5] - Johnson Controls International plc reported an adjusted EPS of $1.05 and sales of $6.1 billion, representing a 6% organic increase year-over-year, with an 11% growth in backlog [6] - The New York Times Company added 460,000 digital-only subscribers, boosting total revenue by 9.5% year-over-year to $700.8 million [7] Media and Global Trade Developments - China's Foreign Minister announced willingness to negotiate a free trade agreement with the European Union, emphasizing cooperation over rivalry [9] - The New York Times Company demonstrated strength in digital transformation, contributing to its revenue growth [7] Crude Oil Markets Face Headwinds - WTI crude oil prices are trading near $60.59, facing downward pressure from a stronger U.S. dollar and increased U.S. crude inventories [10] - OPEC+ has paused output hikes for Q1 2026, agreeing to a modest increase in December, but market sentiment remains cautiously bearish [10]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...